MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 105 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $17,491,000 | +133.9% | 14,106 | +481.0% | 0.00% | – |
| Q1 2017 | $7,478,000 | -78.7% | 2,428 | -71.8% | 0.00% | – |
| Q4 2016 | $35,129,000 | -45.6% | 8,610 | -15.3% | 0.00% | – |
| Q3 2016 | $64,522,000 | +152.5% | 10,161 | +114.4% | 0.00% | – |
| Q2 2016 | $25,549,000 | -87.2% | 4,740 | -81.2% | 0.00% | – |
| Q4 2015 | $198,954,000 | +2.1% | 25,184 | +10.0% | 0.00% | – |
| Q3 2015 | $194,879,000 | +72.3% | 22,900 | +150.2% | 0.00% | – |
| Q2 2015 | $113,131,000 | +309.4% | 9,153 | +293.5% | 0.00% | – |
| Q1 2015 | $27,633,000 | -46.6% | 2,326 | -60.5% | 0.00% | – |
| Q3 2014 | $51,723,000 | +2490.0% | 5,891 | +2050.0% | 0.00% | – |
| Q2 2014 | $1,997,000 | -63.7% | 274 | -78.1% | 0.00% | – |
| Q1 2014 | $5,501,000 | -17.8% | 1,253 | 0.0% | 0.00% | – |
| Q4 2013 | $6,691,000 | -93.2% | 1,253 | -95.2% | 0.00% | – |
| Q3 2013 | $98,714,000 | -59.5% | 26,046 | -28.1% | 0.00% | – |
| Q2 2013 | $243,929,000 | – | 36,245 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lagoda Investment Management, L.P. | 2,211,880 | $17,474,000 | 4.63% |
| Parametrica Management Ltd | 21,228 | $168,000 | 1.11% |
| GARRISON BRADFORD & ASSOCIATES INC | 82,700 | $653,000 | 0.73% |
| Virtus ETF Advisers LLC | 33,570 | $265,000 | 0.73% |
| Opus Point Partners Management, LLC | 122,500 | $968,000 | 0.64% |
| NEXTHERA CAPITAL LP | 36,000 | $284,000 | 0.40% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 7,255,815 | $57,321,000 | 0.39% |
| Cannell & Co. | 1,051,178 | $7,751,000 | 0.25% |
| Tekla Capital Management LLC | 853,787 | $6,745,000 | 0.24% |
| STONERIDGE INVESTMENT PARTNERS LLC | 208,282 | $1,645,000 | 0.22% |